Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Breakfast News - Osford BioDynamics, Range Resources, Arix Bioscience and more...

Breakfast News - Osford BioDynamics, Range Resources, Arix Bioscience  and more...

Small Cap Breakfast

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

956*

Total number of AIM Companies trading:

907*

*as at close of business 15 March 2018

 

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

136*

Total number of Standard List Companies trading:

123*

*as at close of business 15 March 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

88*

Total number of NEX Growth Market Companies trading:

82*                

*as at close of business 15 March 2018

                                 *A corporate client of Hybridan LLP

 **  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

              

 Dish of the day

 Energean Oil & Gas—Seeking gross proceeds of c.$500m. Independent oil and gas exploration and production company focused on exploration, development and production of assets in the Eastern Mediterranean .  Raised $460m/£330m gross at  £4.55. Mkt Cap £696m. Main Market premium . ENOG.L

 

Off the menu   

Trinity Capital has left AIM pursuant to a voluntary liquidation.                                 

 

What’s cooking in the IPO kitchen?

NEX Exchange

Sativa Investments Due 29 Mar. Raising £1m at 1p. Mkt cap £4m.  Investment Vehicle  for investment opportunities and acquisitions in companies which are well-placed to take advantage of the dynamic regulatory environment surrounding legal Medicinal Cannabis.

AIM

Kore Potash— advanced stage mineral exploration and development company whose primary asset is its interest in the Sintoukola Project, a potash project located in the Republic of Congo. ) Measured, Indicated and Inferred Mineral Resource of 5,953Mt at an average grade of 22.0% KCl. Offer TBA. Due end March.

Perfomatrix PLC, a global end to end Performance Marketing technology and services company headquartered in the UK, is looking to join AIM in early April 2018, offer TBC

Crusader Resources, an ASX-listed public company incorporated in Australia, which is primarily focused on the exploration and development of gold assets in Brazil. Offer TBC, expected late March.

SimplyBiz, a Financial Services Firm, looking to join AIM raising £30m via placing and £34.6m via a sale of existing ordinary shares at 170p giving a market cap of £130m. Expected 4 April

Bacanora Lithium—Readmission. No new money. Mkt cap £140m. Due 21 March. the new holding company for Bacanora Minerals Ltd 

Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area. Vendor placing and new funds to a total of €225m, Target gross proceeds €207m. Expected Mid March

Polarean  - Medical drug-device combination company operating in the high resolution medical imaging market. Offer TBC. Due 26 March

 

Main Market Specialist Funds

Life Settlement—closed-ended investment company whose principal activities will be to support and manage portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the US.  Due 6 Mar.

Main Market Premium Listing

Gore Street Energy Storage Fund—Seeking to raise £100m for the purposes of investment in a diversified portfolio of utility scale energy storage projects.  Due 12 April.

Broker and investment platform operator AJ Bell reported to be considering London float with a valuation at £50m. 

 

Breakfast buffet

Clear Leisure (LON:CLP) 0.93p £3.66m

Placing of £300k at 0.7p from the investment company with a portfolio of companies primarily encompassing the leisure and real estate sectors mainly in Italy.

The Placing, which was over-subscribed, is with certain existing and new investors. The funds raised will be used for working capital purposes, legal costs associated with debt recovery and to continue the development of the Company’s cryptocurrency strategy.

The focus of management is to pursue the monetisation of all of the Company’s existing assets, through selected realisations, court-led recoveries of misappropriated assets and substantial debt-recovery processes. 

 

Arix Bioscience (LON:ARIX) 218p £209.6m

Results of capital raise—circa £87m at 225p.

“Since the inception of Arix, just over 2 years ago, we have raised in excess of £250m to pursue our goal of accessing breakthroughs in life sciences and accelerating their development into important new medical treatments.

"We have built interests in 13 promising young businesses, to date, and see significant potential for value creation among them in the year ahead. We continue to evaluate other opportunities in high quality, science-based businesses and the financing announced today will enable us to embrace these for the benefit of our shareholders.”

 

cloudBuy (LON:CBUY) 4.8p £6.26m

FYDec17 results from the provider of cloud solutions to buyers and sellers.  Revenue for the year was £1.5m a reduction of 12% on 2016. This reduction was as a result of the end of 2 contracts in Q4 2016 and the continuing reduction in Company Formations revenue.  Operating loss excluding share based payments was £2.18m a reduction of 35% on 2016. Continuing cost initiatives are expected to result in a further reduction in administrative expenses in 2018. “Further investment of £1.7m from Roberto Sella in Dec 2017. This funding is anticipated to be sufficient to take the business to profitability based on forecast revenue from existing customers.”

“The main strategy for growth remains PHBChoices where we expect to see revenue in 2018 growing from the initial current level.”

 

Range Resources (RRL.L) 0.2p £13.29m

HY Dec17 results from the international exploration, development and production company, with interests in oil and gas projects in Trinidad and Indonesia, as well as oilfield services business in Trinidad. Financial performance has materially improved with a 77% reduction in loss before tax to $8.5m (prior year: $37.8m); Revenues increased by 39% to $5.4m (prior year: $3.9m), principally due to an increase in production; 

Trinidad: The average production for the period of 605 bopd was 22% higher than comparable prior year; Increase in production is mainly attributed to the ongoing waterflood programme, selective development drilling and workovers; Independent Competent Persons Report published confirming net 2P reserves of 16 MMstb and net 2C contingent resources of 8 MMstb.

Indonesia: The Company has been building an experienced operating team, and undertaking initial geological and geophysical studies; Upcoming work programme and budget are being finalised; and   Independent CPR published confirming net 2C contingent resources of 10.9 Bscf and 3.1 MMstb.

 

Osford BioDynamics  (LON:OBD) 160p £144.3m

The biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has presented its latest EpiSwitch™ biomarker data in a plenary talk entitled: "Multi-Center Biomarker Development for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis", at the 6th World CNS Summit in Boston, MA, 20-22 February 2018. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a type of motor neuron disease. 

OBD has demonstrated on the MIQE-compliant qPCR format of EpiSwitch™ that there are prognostic biomarkers that capture rates of development and stages of ALS. These results define actionable stratifications for individual patients on the basis of high resolution detection of chromosome conformations and regulatory genome 3D architecture.  This is a “unique opportunity to make a highly valuable contribution to improved patient care, clinical decisions and evidence of efficacy in drug treatments."

 

Shield Therapeutics (LON:STX) 17.5p £20.37m

Update following detailed analyses of the data from the double-blind period of the AEGIS-CKD study, which it has presented to the FDA in a previously scheduled pre-NDA meeting. Following a review of all enrolled subjects who completed the initial 16-week placebo-controlled portion of the study, a small number of patients in both treatment arms were identified as experiencing pre-specified events that could have led to withdrawal but, as permitted in the study protocol,  they remained.  Further analyses of the data have been conducted using an amended statistical analysis plan that removed the confounding data. As a result of these revised analyses, patients treated with Feraccru demonstrated a statistically significant response (p=0.0149) in haemoglobin levels after 16 weeks of treatment compared to placebo (difference 0.52g/ dl (CI 0.102, 0.930. Whilst the Company believes there is a clear and robust rationale for the analyses of the dataset as outlined, there can be no certainty that the FDA will accept the approach taken.  

 

Graphene NanoChem (LON:GRPH) 1.93p £3.89m

Pursuant to AIM Rule 1 the shares will delist on 19 March.

“The Company is pleased to report progress in advancing the Proposed Acquisition, including substantial work on the legal and financial due diligence. The Directors believe the Proposed Acquisition, if completed, would be transformational for the Company and its shareholders and will continue to work with their respective advisers to complete the necessary documentation to execute the Proposed Acquisition.

It is contemplated that upon completion of the Proposed Acquisition the Company will be undertaking an IPO, with a view to being admitted to trading on AIM in conjunction with the execution of a simultaneous fundraise, the proceeds of which are intended to be used to finance the development of the enlarged group going forward.”

 

Techfinancials (LON:TECH) 21.6p £15.67m

“TechFinancials is pleased to provide an update on significant progress at Cedex Holdings Ltd, a company in which it currently has a 2% interest and an option to acquire a further 90%, which would give TechFinancials up to 92% of CEDEX or 87.4% on a fully diluted basis. CEDEX is a blockchain-based on-line exchange for diamonds.

As scheduled, CEDEX will launch its token pre-sale event today, 16 March 2018 at 10.00am. CEDEX has set the sale price of the CEDEX coins at 1 Ether = 900 CEDEX coins.

The CEDEX management team has indicated that there is strong demand from potential participants in the event, which is expected to last up to 10 days.”

We could see no forecasts,

 

Conviviality LON:(CVR) 101.2p £185.48m

Further to the update announcement on 14 March 2018, the Company has been actively engaging with its stakeholders while it continues to work through its funding requirements: 

Customers and suppliers remain supportive of the Company and are working closely and constructively with the Company at this time;

We have had constructive discussions with our lenders which are on-going;

The Company has engaged with HM Revenues and Customs ("HMRC") regarding the £30m payment due on the 29 March 2018. HMRC has been receptive to our needs and these discussions continue; and

The Company is engaging with its advisers and broker regarding the possibility of an equity fundraise to effect a recapitalisation of the business.

FYApr18E rev £1.7bn and PBT £46.1m.  pEc.6x.

 

 

 

 

Join our Crypto, Blockchain and Cannabis Telegram group here

Important Risk Warnings and Disclaimers 

This report is published by Beaufort Securities Ltd ("Beaufort Securities"). Beaufort Securities Ltd is Authorised and Regulated by the Financial Conduct Authority and is a Member of the London Stock Exchange. 

RELIANCE ON THIS NOTE FOR THE PURPOSE OF ENGAGING IN ANY INVESTMENT ACTIVITY MAY EXPOSE YOU TO A SIGNIFICANT RISK OF LOSING ALL OF THE FUNDS, PROPERTY OR OTHER ASSETS INVESTED OR OF INCURRING ADDITIONAL LIABILITY. 

This document is not an offer to buy or sell any security or currency. This document does not provide you with individually tailored investment advice. It has been prepared without regard to the your financial circumstances and objectives The appropriateness of a particular investment or currency will depend on your individual circumstances and objectives. The investments and shares referred to in this document may not be suitable for you. 

This research is non-independent and is classified as a Marketing Communication under FCA rules. As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition on dealing ahead of the dissemination of investment research in COBS 12.2.5. However Beaufort Securities has adopted internal procedures which prohibit analysts from dealing ahead of non-independent research, except for legitimate market making and fulfilling clients' unsolicited orders. 

By receiving this document, you will not be deemed a client or provided with the protections afforded to clients of Beaufort Securities. When distributing this document, Beaufort Securities is not acting for you and will not be responsible for providing advice to you in relation to this document. Accordingly, Beaufort Securities will not be responsible to you for providing the protections afforded to its clients. 

Beaufort Securities may effect transactions in shares mentioned herein and may take proprietary trading positions in those shares, and may receive remuneration for the publication of its research and for other services. Beaufort Securities may be a shareholder in any of the companies mentioned in this report. Accordingly, this document may not be considered as objective or impartial. Additionally, information may be available to Beaufort Securities or the Group, which is not reflected in this material. The remuneration of the author of this report is not tied to the recommendations on any shares mentioned nor to the any transactions undertaken by Beaufort Securities or any affiliate company. Further information on Beaufort Securities' policy regarding potential conflicts of interest in the context of investment research and Beaufort Securities' policy on disclosure and conflicts in general are available on request. Please refer to http://www.beaufortsecurities.com/important-info. 

Past performance is not a guarantee of future performance. Investments may go down in value as well as up and you may not get back the full amount invested. The listing requirements for securities listed on AIM or the ICAP Securities & Derivatives Exchange are less demanding and trading in them may be less liquid than main markets. This may make it more difficult to buy and sell these securities. 

 

This document includes certain statements, estimates, and projections with respect to the anticipated future performance of securities listed on stock exchanges and as to the market for these shares. Such statements, estimates, and projections are based on information that we consider reliable and may reflect various assumptions made concerning anticipated economic developments, which have not been independently verified and may or may not prove correct. No representation or warranty is made as to the accuracy of such statements, estimates, and projections or as to its fitness for the purpose intended and it should not be relied upon as such. Opinions expressed are our current opinions as of the date appearing on this material only and may change without notice. Other third parties may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views, and analytical methods of the analysts who prepared them. This report has not been disclosed to any of the companies mentioned herein prior to its publication. 

This document is based on information Beaufort Securities has received from publicly available reports and industry sources. Beaufort Securities may not have verified all of this information with third parties. Neither Beaufort Securities nor its advisors, directors or employees can guarantee the accuracy, reasonableness or completeness of the information received from any sources consulted for this publication, and neither Beaufort Securities nor its advisors, directors or employees accepts any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by the applicable law). You should not rely on this document and should not use it substitution for the exercise of the independent judgment of yourself or your adviser. 

The information contained in this document is confidential and is solely for use of those persons to whom it is addressed and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Other persons who receive this document should not rely on it. Beaufort Securities, its directors, officers and employees may have positions in the securities mentioned herein.

 

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use